Showing results (361-370 of 372) with videos related to

Sort By:
Pageof 38
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 1995
Detection of occult melanoma cells in blood with a multiple-marker polymerase chain reaction assayD S Hoon, Y Wang, P S Dale, et al.
Cancer|February 15, 1984
Clinical thermochemotherapy. A controlled trial in advanced cancer patientsF K Storm, A W Silberman, K R Ramming, et al.
European Journal of Cancer (Oxford, England : 1990)|April 30, 2002
Ultrastaging of early colon cancer using lymphatic mapping and molecular analysisA J Bilchik, D Nora, R A E M Tollenaar, et al.
Oncogene|June 30, 2009
Functional RET G691S polymorphism in cutaneous malignant melanomaN Narita, A Tanemura, R Murali, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 22, 2001
Molecular staging of early colon cancer on the basis of sentinel node analysis: a multicenter phase II trialA J Bilchik, S Saha, D Wiese, et al.
Annals of Surgery|October 1, 1992
Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccineD L Morton, L J Foshag, D S Hoon, et al.
Neurosurgery|January 23, 1999
Gamma knife radiosurgery for metastatic melanoma: an analysis of survival, outcome, and complicationsS D Lavine, Z Petrovich, A A Cohen-Gadol, et al.
The British Journal of Dermatology|February 2, 2012
Aberrant hypermethylation in primary tumours and sentinel lymph node metastases in paediatric patients with cutaneous melanomaK T Huynh, Y Takei, C Kuo, et al.
Annals of Surgery|October 16, 1999
Validation of the accuracy of intraoperative lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma: a multicenter trial. Multicenter Selective Lymphadenectomy Trial GroupD L Morton, J F Thompson, R Essner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 24, 1999
Advantages of concurrent biochemotherapy modified by decrescendo interleukin-2, granulocyte colony-stimulating factor, and tamoxifen for patients with metastatic melanomaS J O'Day, G Gammon, P D Boasberg, et al.
Pageof 38